# Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

> **NCT06210854** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 48 (estimated)

## Conditions studied

- HPV Infection

## Interventions

- **BIOLOGICAL:** pBI-11 (3 doses)
- **BIOLOGICAL:** pBI-11 (1 dose)
- **BIOLOGICAL:** Placebo (2 doses)

## Key facts

- **NCT ID:** NCT06210854
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2029-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06210854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06210854, "Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06210854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*